Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

Exclusion Criteria

• •Have any clinical evidence of local infection of the index lesion
• •Use of prior or concomitant medication (Any investigational drug within 30 days, Immunotherapy or cytotoxic chemotherapy within 60 days, Systemic steroidal therapy within 30 days, and topical steroidal therapy within 14 days)
• •History of sensitivity to any component of the treatment
• •Neurological, cardiovascular, respiratory, hepatic, renal, or metabolic disease likely to interfere with the subject's participation in or completion of the study (At the discretion of investigator, participants with cardiomyopathy can participate)
• •Current or former malignancy, including a history of squamous cell carcinomas
• •Arterial or venous disorder resulting in ulcerated wounds
• •Uncontrolled diabetes mellitus
• •Pregnancy or breastfeeding during the study
• •Girls or women who have had menarche but have not completed menopause
• •Any condition or situation likely to cause the subject to be unable or unwilling to participate in the study procedures